According to this latest study, the 2021 growth of Vaccine Adjuvants will have significant change from previous year. By the most conservative estimates of global Vaccine Adjuvants market size (most likely outcome) will be a year-over-year revenue growth rate of % in 2021, from US$ 635.9 million in 2020. Over the next five years the Vaccine Adjuvants market will register a 9.3% CAGR in terms of revenue, the global market size will reach US$ 907.7 million by 2026.

This report presents a comprehensive overview, market shares, and growth opportunities of Vaccine Adjuvants market by product type, application, key manufacturers and key regions and countries.

Segmentation by type: breakdown data from 2016 to 2021, in Section 2.3; and forecast to 2026 in section 11.7.
Aluminum Adjuvant
Emulsions Adjuvant
Others

Segmentation by application: breakdown data from 2016 to 2021, in Section 2.4; and forecast to 2026 in section 11.8.
Human Vaccine Adjuvants
Veterinary Vaccine Adjuvants

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in Chapter 3.
GSK
CSL Limited
Croda
SEPPIC
Novavax
SPI Pharma
Phibro
SDA BIO
Invivogen
Tj Kaiwei
OZ Biosciences
Brenntag Biosector
MVP Laboratories
Zhuoyue
Aphios